Sugi Predict

Sugi Predict / Targets / UGT1A3

UGT1A3

UDP-glucuronosyltransferase 1A3 · P35503 · UGT1A3 on Sugi Atlas →

74 patent compounds predicted against UGT1A3, 65 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL22528644 SCHEMBL22528644 1.00 1/20
SCHEMBL305411 SCHEMBL305411 0.75 1/20
SCHEMBL668045 SCHEMBL668045 0.72 1/20
SCHEMBL2916013 SCHEMBL2916013 0.71 1/20
SCHEMBL2967226 SCHEMBL2967226 0.69 1/20
SCHEMBL2960859 SCHEMBL2960859 0.69 1/20
SCHEMBL2963278 SCHEMBL2963278 0.68 1/20
SCHEMBL2963281 SCHEMBL2963281 0.68 1/20
SCHEMBL2960667 SCHEMBL2960667 0.68 1/20
SCHEMBL2956891 SCHEMBL2956891 0.67 1/20
SCHEMBL966228 SCHEMBL966228 0.66 1/20
SCHEMBL2961264 SCHEMBL2961264 0.65 1/20
SCHEMBL1108362 SCHEMBL1108362 0.65 1/20
SCHEMBL669409 SCHEMBL669409 0.65 1/20
SCHEMBL2960696 SCHEMBL2960696 0.65 1/20
SCHEMBL1100281 SCHEMBL1100281 0.64 1/20
SCHEMBL2959647 SCHEMBL2959647 0.62 1/20
SCHEMBL1100631 SCHEMBL1100631 0.61 1/20
SCHEMBL2965022 SCHEMBL2965022 0.61 1/20
SCHEMBL6829363 SCHEMBL6829363 0.60 1/20

Clinical trials — most relevant to UGT1A3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Cholestatic Drug-induced Liver Injury PHASE4UNKNOWN
Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral Therapy PHASE4COMPLETED
Effect of Genetic Polymorphisms of UGT on the PKs of Indapamide in Egyptians PHASE4UNKNOWN
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer PHASE3COMPLETED
Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial PHASE3UNKNOWN
Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer PHASE2COMPLETED
CBD for Pain Following Orthopedic Shoulder Surgery PHASE1/PHASE2RECRUITING
Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer PHASE2COMPLETED
A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With Ethionamide PHASE2RECRUITING
A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1 PHASE2RECRUITING
Oral Cannabidiol for Opioid Withdrawal PHASE1/PHASE2COMPLETED
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial PHASE2ACTIVE_NOT_RECRUITING
Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer PHASE2COMPLETED
Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin PHASE1COMPLETED
A Phase I Study to Assess the Safety and Tolerability of BL0006 for Patients With Advanced Solid Tumours PHASE1UNKNOWN
Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors PHASE1UNKNOWN
First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors PHASE1COMPLETED
Study of NK012 in Patients With Refractory Solid Tumors PHASE1COMPLETED
MLN8237 to Treat Children With Relapsed/Refractory Solid Tumors PHASE1COMPLETED
Irinotecan in Treating Asian Patients With Solid Tumors PHASE1COMPLETED
Safety Study of IHL-305 (Irinotecan Liposome Injection) to Treat Advanced Solid Tumors PHASE1COMPLETED
Contribution of UGT2B17 to the Pharmacokinetics of Diclofenac EARLY_PHASE1RECRUITING
Genetic Study of Patients Previously Treated With Flavopiridol on Clinical Trial NCI-97-C-0171C nanCOMPLETED
Genetic Polymorphisms in UGT1A6 and UGT2B7 in Asian Population: Association With Lung Cancer Phenotype nanUNKNOWN
Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants nanCOMPLETED
Genetic Trial to Study Diarrhea in Patients With Stage III Colon Cancer Who Are Receiving Chemotherapy nanCOMPLETED
Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant nanRECRUITING
Exploration of the Dynamic Changes and Mechanisms of the Immune Microenvironment in Advanced Colorectal Cancer Treated With IBI363 Combination Therapy nanRECRUITING
PhaRmacOgenetics and Therapeutic Drug Monitoring In SchizophrEnia nanNOT_YET_RECRUITING
Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a UGT1A3 binder may also engage these)

ProteinNameSimilarity
UGT1A4 UDP-glucuronosyltransferase 1A4 1.000 landscape →
P35504 — 1.000 P35504 →
Q64550 — 1.000 Q64550 →
Q64638 — 0.999 Q64638 →
Q64637 — 0.999 Q64637 →
UGT1A1 UDP-glucuronosyltransferase 1A1 0.998 landscape →
P20720 — 0.998 P20720 →
P70691 — 0.996 P70691 →
P08430 — 0.995 P08430 →
Q28612 — 0.995 Q28612 →
Q64435 — 0.994 Q64435 →
Q63886 — 0.993 Q63886 →
UGT1A6 UDP-glucuronosyltransferase 1A6 0.990 landscape →
Q64634 — 0.988 Q64634 →
Q6ZQM8 — 0.987 Q6ZQM8 →
Q28611 — 0.984 Q28611 →
Q64633 — 0.983 Q64633 →
Q62452 — 0.981 Q62452 →
P36510 — 0.962 P36510 →
Q80X89 — 0.961 Q80X89 →
Q6PDD0 — 0.960 Q6PDD0 →
P0DTE5 — 0.958 P0DTE5 →
P36512 — 0.958 P36512 →
Q9R110 — 0.956 Q9R110 →
P54855 — 0.956 P54855 →
O02663 — 0.956 O02663 →
UGT2B17 UDP-glucuronosyltransferase 2B17 0.955 landscape →
Q8BWQ1 — 0.954 Q8BWQ1 →
UGT1A8 UDP-glucuronosyltransferase 1A8 0.954 landscape →
P36514 — 0.953 P36514 →